Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.81 [0.68, 0.97] | | < 1 | | 59% | 3 studies (3/-) | 99.0 % | some concern | not evaluable | moderate | crucial | - |
deaths (OS) (extension) | 0.66 [0.55, 0.80] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
PFS (extension) | 0.68 [0.57, 0.82] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
progression or deaths (PFS) | 0.76 [0.63, 0.92] | | < 1 | | 54% | 4 studies (4/-) | 99.8 % | some concern | not evaluable | moderate | important | - |
objective responses (ORR) | 1.46 [1.03, 2.08] | | > 1 | | 71% | 4 studies (4/-) | 98.4 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
AE (any grade) | 0.51 [0.27, 0.96] | | < 1 | | 0% | 1 study (1/-) | 98.2 % | NA | not evaluable | | non important | - |
AE (grade 3-4) | 1.02 [0.76, 1.37] | | < 1 | | 0% | 1 study (1/-) | 44.6 % | NA | not evaluable | | non important | - |
AE leading to death (grade 5) | 2.19 [1.17, 4.11] | | < 1 | | 0% | 1 study (1/-) | 0.7 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (any grade) | 1.43 [0.97, 2.10] | | < 1 | | 0% | 1 study (1/-) | 3.5 % | NA | not evaluable | | non important | - |
AE leading to treatment discontinuation (grade 3-4) | 2.14 [1.32, 3.47] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
SAE (any grade) | 1.93 [1.22, 3.04] | | < 1 | | 0% | 1 study (1/-) | 0.2 % | NA | not evaluable | | non important | - |
STRAE (any grade) | 1.90 [1.55, 2.32] | | < 1 | | 0% | 4 studies (4/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
STRAE (grade 3-4) | 1.83 [1.47, 2.28] | | < 1 | | 0% | 4 studies (4/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
TRAE (any grade) | 0.78 [0.38, 1.62] | | < 1 | | 91% | 4 studies (4/-) | 74.8 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) | 0.94 [0.62, 1.42] | | < 1 | | 83% | 4 studies (4/-) | 61.5 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to death (grade 5) | 1.25 [0.61, 2.53] | | < 1 | | 0% | 3 studies (3/-) | 27.2 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (any grade) | 2.62 [1.73, 3.95] | | < 1 | | 61% | 4 studies (4/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (grade 3-4) | 3.56 [2.57, 4.94] | | < 1 | | 0% | 4 studies (4/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
Adrenal insufficiency TRAE (grade 3-4) | 6.74 [0.82, 55.04] | | < 1 | | 0% | 2 studies (2/-) | 3.8 % | some concern | not evaluable | moderate | non important | - |
Alopecia TRAE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 0.17 [0.06, 0.46] | | < 1 | | 69% | 4 studies (4/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
Asthenia TRAE (grade 3-4) | 0.59 [0.21, 1.68] | | < 1 | | 39% | 4 studies (4/-) | 83.8 % | some concern | not evaluable | moderate | non important | - |
Colitis TRAE (grade 3-4) | 11.58 [1.50, 89.46] | | < 1 | | 0% | 2 studies (2/-) | 1.0 % | some concern | not evaluable | moderate | non important | - |
Constipation TRAE (grade 3-4) | 0.69 [0.11, 4.24] | | < 1 | | 0% | 4 studies (4/-) | 65.6 % | some concern | not evaluable | moderate | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.84 [0.40, 1.79] | | < 1 | | 0% | 4 studies (4/-) | 67.2 % | some concern | not evaluable | moderate | non important | - |
Diabetes TRAE (grade 3-4) | 1.90 [0.06, 56.82] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 3.83 [1.72, 8.51] | | < 1 | | 0% | 4 studies (4/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
Fatigue TRAE (grade 3-4) | 1.46 [0.64, 3.34] | | < 1 | | 29% | 4 studies (4/-) | 18.3 % | some concern | not evaluable | moderate | non important | - |
Febrile neutropenia TRAE (grade 3-4) | 1.38 [0.60, 3.15] | | < 1 | | 0% | 1 study (1/-) | 22.3 % | NA | not evaluable | | non important | - |
Hepatitis TRAE (grade 3-4) | 13.52 [0.76, 239.13] | | < 1 | | 0% | 1 study (1/-) | 3.9 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 1.90 [0.06, 56.82] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Hypophysitis TRAE (grade 3-4) | 1.90 [0.06, 56.82] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Hypothyroidism TRAE (grade 3-4) | 2.72 [0.39, 19.13] | | < 1 | | 0% | 3 studies (3/-) | 15.9 % | some concern | not evaluable | moderate | non important | - |
Increased ALT TRAE (grade 3-4) | 2.46 [0.47, 12.75] | | < 1 | | 0% | 1 study (1/-) | 14.3 % | NA | not evaluable | | non important | - |
Increased lipase level TRAE (grade 3-4) | 7.55 [2.24, 25.47] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
Maculopapular rash TRAE (grade 3-4) | 4.93 [0.57, 42.41] | | < 1 | | 0% | 1 study (1/-) | 7.4 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.59 [0.20, 1.77] | | < 1 | | 37% | 4 studies (4/-) | 82.7 % | some concern | not evaluable | moderate | non important | - |
Nephritis TRAE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.05 [0.00, 0.74] | | < 1 | | 84% | 4 studies (4/-) | 98.5 % | some concern | not evaluable | moderate | non important | - |
Pneumonitis TRAE (grade 3-4) | 7.74 [0.96, 62.17] | | < 1 | | 0% | 1 study (1/-) | 2.8 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 3.67 [0.73, 18.44] | | < 1 | | 0% | 4 studies (4/-) | 5.8 % | some concern | not evaluable | moderate | non important | - |
Rash TRAE (grade 3-4) | 5.99 [1.42, 25.24] | | < 1 | | 0% | 4 studies (4/-) | 0.7 % | some concern | not evaluable | moderate | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 0.21 [0.01, 8.21] | | < 1 | | 84% | 2 studies (2/-) | 79.4 % | some concern | not evaluable | moderate | non important | - |
Vomiting TRAE (grade 3-4) | 0.26 [0.06, 1.14] | | < 1 | | 56% | 4 studies (4/-) | 96.3 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
Alopecia AE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
Anaemia AE (grade 3-4) | 0.12 [0.05, 0.28] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Asthenia AE (grade 3-4) | 0.86 [0.36, 2.05] | | < 1 | | 0% | 1 study (1/-) | 63.4 % | NA | not evaluable | | non important | - |
Back pain AE (grade 3-4) | 0.63 [0.10, 3.80] | | < 1 | | 0% | 1 study (1/-) | 69.2 % | NA | not evaluable | | non important | - |
Constipation AE (grade 3-4) | 1.90 [0.17, 21.07] | | < 1 | | 0% | 1 study (1/-) | 30.1 % | NA | not evaluable | | non important | - |
Cough AE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
Decreased appetite AE (grade 3-4) | 1.43 [0.40, 5.11] | | < 1 | | 0% | 1 study (1/-) | 29.1 % | NA | not evaluable | | non important | - |
Diarrhoea AE (grade 3-4) | 2.12 [0.73, 6.17] | | < 1 | | 0% | 1 study (1/-) | 8.4 % | NA | not evaluable | | non important | - |
Dyspnoea AE (grade 3-4) | 1.11 [0.37, 3.33] | | < 1 | | 0% | 1 study (1/-) | 42.7 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 1.31 [0.52, 3.31] | | < 1 | | 0% | 1 study (1/-) | 28.1 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 0.63 [0.18, 2.25] | | < 1 | | 0% | 1 study (1/-) | 76.2 % | NA | not evaluable | | non important | - |
Neutropenia AE (grade 3-4) | 0.01 [0.00, 0.19] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
Pruritus AE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
Pyrexia AE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
Rash AE (grade 3-4) | 0.95 [0.06, 15.23] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
Thrombocytopenia AE (grade 3-4) | 0.03 [0.00, 0.42] | | < 1 | | 0% | 1 study (1/-) | 99.4 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 0.13 [0.02, 1.09] | | < 1 | | 0% | 1 study (1/-) | 96.9 % | NA | not evaluable | | non important | - |
Weight decreased AE (grade 3-4) | 2.86 [0.30, 27.64] | | < 1 | | 0% | 1 study (1/-) | 18.3 % | NA | not evaluable | | non important | - |